Olgerd Duchnevič

Olgerd Duchnevič

Auto-generated profile, based on publicly available information

Olgerd Duchnevič

Ludwik Rydygier Memorial Hospital in Cracow, Osiedle Złotej Jesieni 1, 31-826

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 February 2024 in Journal of Education, Health and Sport
Verified
Journal Article
Open access
PDF file
MSMichał Sęk
Michał Sęk
ODOlgerd Duchnevič
Olgerd Duchnevič
IGIwona Galasińska
Iwona Galasińska
KHKatarzyna Hajduk-Maślak
Katarzyna Hajduk-Maślak
ASAleksandra Szypuła
Aleksandra Szypuła
ASAdrianna Skóra
Adrianna Skóra
Introduction: IBD-related arthritis (spondyloarthropathy) is the most common extraintestinal manifestation (EIM) of inflammatory bowel disease (IBD) and is often considered a formidable clinical challenge. Emergence of TNFα-antagonists has revolutionised the clinical approach to management of IBD-related arthritis and remains the mainstay of the therapy. However, its use presents several limitations, underscoring the need for new treatment modalities. Recently, new agents have been approved for the management of IBD, although their influence on IBD-related arthritis has been scarcely investigated. Aim of the Study: The aim of the study was to collect and analyse current literature regarding the efficacy of new agents used for treating IBD-related arthritis. Methods and Materials: Extensive research was conducted using the PubMed, ScienceDirect database and Google Scholar, with the primary focus on literature from the past 5 years. Firstly, potential novel treatment options for IBD-related arthritis were obtained. The names of the drugs were juxtaposed with terms related to “IBD-related arthritis” to gather data regarding their efficacy in said condition. Additionally, references from selected articles were included in the analysis. Results: Emerging treatment options show promising results in achieving remission of IBD-related arthritis. However, our study revealed research gap as the current literature lacks large-scale, prospective studies that assess the efficacy of the aforementioned agents in achieving a resolution of IBD-related arthritis. Therefore, the results of our study encourage further research, with special emphasis on large-scale randomised controlled trials.

13 February 2024 in Journal of Education, Health and Sport
Verified
Journal Article
Open access
PDF file
ODOlgerd Duchnevič
Olgerd Duchnevič
IGIwona Galasińska
Iwona Galasińska
BMBeniamin Michalik
Beniamin Michalik
KHKatarzyna Hajduk-Maślak
Katarzyna Hajduk-Maślak
ASAleksandra Szypuła
Aleksandra Szypuła
ASAdrianna Skóra
Adrianna Skóra
Introduction: Rheumatoid arthritis (RA) is an inflammatory autoimmune disease that often causes ocular complications, of which keratoconjunctivitis sicca (KCS), scleritis and episcleritis are the most common entities. When left untreated, they can adversely affect eye health and cause vision loss in severe cases. Therefore, early and effective treatment of ophthalmic complications may significantly improve visual outcomes in patients with rheumatoid arthritis. Aim of the study: The aim of the study was to compile and analyze the current literature on the treatment of the most prevalent ocular manifestation associated with RA. Special emphasis was placed on recently approved drugs and those in late-stage clinical trials. Methods and materials: Publication research was conducted using the PubMed database and Google Scholar with a primary focus on literature from the past 10 years. Firstly, common ocular complications of rheumatoid arthritis were identified and relevant treatment modalities were extracted for further analysis. Finally, the names of relevant drugs or drug classes were used along with the names of the aforementioned disease entities to discover clinical trials regarding their efficacy and safety. Additionally, references from selected manuscripts were included. Summary: The landscape of treatment for ocular complications associated with RA offers a promising future for patients and clinicians. Three new therapeutic modalities for dry eye disease have been approved in 2023, and three additional drugs are in late-stage clinical trials. Furthermore, recent advances in biologic therapy have shown considerable promise in treating scleritis, especially in patients refractory to conventional treatment or with severe symptoms of the disease.